Based in New York, Messrs. Duty, Gerber and Shin join an existing team led by Alan Schwartz, Executive Chairman of Guggenheim Partners, and Ken Springer, Senior Managing Director.
'Stuart, Ron and Barry will add significant expertise to our growing healthcare platform', said Schwartz. 'This sector is core to our investment banking business, and their deep industry relationships and experience, especially in equity new issuance and life sciences M&A, will be invaluable as we continue to expand our franchise'.
With over 20 years of experience in the life sciences sector, Duty joins as a Senior Managing Director with responsibility for helping build the healthcare practice. Previously, he was Co-Head of Healthcare Investment Banking at Piper Jaffray. Prior to that, Duty held senior-level positions in healthcare investment banking at Montgomery Securities and Kidder Peabody & Co.
Also from Piper Jaffray, Messrs. Gerber and Shin are joining Guggenheim Securities as Managing Director and Vice President, respectively. Together, they have over 25 years experience advising specialty pharmaceutical and biotechnology companies across a range of financing and M&A transactions.
'Ron, Barry and I are pleased to join the Guggenheim Securities team', added Duty. 'The firm's accomplishments in the healthcare sector, as well as the steady growth of the entire investment banking franchise, are highly regarded throughout the industry. We look forward to building on the success with new mandates and advisory relationships'.
Since its launch in 2009, Guggenheim Securities' healthcare investment banking and advisory practice has advised Pfizer on its $2.4 billion sale of Capsugel to KKR and Merck KGaA on its $7 billion acquisition of Millipore, in addition to numerous mid-market transactions. Guggenheim Securities is also building a healthcare-focused sales and trading team, and the firm publishes healthcare market commentary focused on regulatory and legislative issues through its Washington Research Group.